tradingkey.logo

Bausch + Lomb Corp

BLCO
查看詳細走勢圖
16.950USD
+0.050+0.30%
收盤 12/19, 16:00美東報價延遲15分鐘
6.00B總市值
虧損本益比TTM

Bausch + Lomb Corp

16.950
+0.050+0.30%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.30%

5天

-0.24%

1月

+16.41%

6月

+44.50%

今年開始到現在

-6.15%

1年

-5.83%

查看詳細走勢圖

TradingKey Bausch + Lomb Corp股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Bausch + Lomb Corp當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名74/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價17.15。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Bausch + Lomb Corp評分

相關信息

行業排名
74 / 208
全市場排名
175 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 14 分析師
持有
評級
17.154
目標均價
+3.59%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Bausch + Lomb Corp亮點

亮點風險
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
業績高增長
公司營業收入穩步增長,連續3年增長27.15%
估值合理
公司最新PE估值-19.69,處於3年歷史合理位
機構加倉
最新機構持股42.63M股,環比增加0.03%
霍華·馬克斯持倉
明星投資者霍華·馬克斯持倉,最新持倉3.25M股

Bausch + Lomb Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Bausch + Lomb Corp簡介

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
公司代碼BLCO
公司Bausch + Lomb Corp
CEOSaunders (Brenton L)
網址https://ir.bausch.com/

常見問題

Bausch + Lomb Corp(BLCO)的當前股價是多少?

Bausch + Lomb Corp(BLCO)的當前股價是 16.950。

Bausch + Lomb Corp 的股票代碼是什麼?

Bausch + Lomb Corp的股票代碼是BLCO。

Bausch + Lomb Corp股票的52週最高點是多少?

Bausch + Lomb Corp股票的52週最高點是18.553。

Bausch + Lomb Corp股票的52週最低點是多少?

Bausch + Lomb Corp股票的52週最低點是10.450。

Bausch + Lomb Corp的市值是多少?

Bausch + Lomb Corp的市值是6.00B。

Bausch + Lomb Corp的淨利潤是多少?

Bausch + Lomb Corp的淨利潤為-317.00M。

現在Bausch + Lomb Corp(BLCO)的股票是買入、持有還是賣出?

根據分析師評級,Bausch + Lomb Corp(BLCO)的總體評級為持有,目標價格為17.154。

Bausch + Lomb Corp(BLCO)股票的每股收益(EPS TTM)是多少

Bausch + Lomb Corp(BLCO)股票的每股收益(EPS TTM)是-0.862。
KeyAI